FDA Decision is Expected Within 90 Days of Initial Submission; However, the Process May be Paused if Additional Information is Requested AUSTIN, TX / ACCESSWIRE / August 8, 2024 / Monogram ...
On October 6, 2024, Monogram (NASDAQ:MGRM) announced it had received an Additional Information Request (“AIR”) from the U.S. Food and Drug Administration (“FDA”) on September 30, 2024, regarding its ...
Zacks Small Cap Research on MSN
MGRM: Monogram’s Potential for 2025 Commercialization of its mBôs Total Knee Arthroplasty Robotic System Supports Price Target of $6.00.
On February 26, 2025, Monogram (NASDAQ:MGRM) announced an update regarding its 510(k) premarket filing submission to the FDA for the company's mBôs TKA System. The company stated it had completed all ...
Application was Submitted on July 19, 2024, Passed the FDA Administrative Review, and is Now Under Substantive Review FDA Decision is Expected Within 90 Days of Initial Submission; However, the ...
AUSTIN, TX / ACCESSWIRE / August 8, 2024 / Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results